Lexaria Announces Exercised Warrants and Options
(OTCQB:LXRP) (CSE:LXX) (the "Company") and Neutrisci International Inc ("Neutrisci") (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed the previously announced joint venture" width="300" height="225" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Lexaria-Corp-boost-1.jpg?resize=300%2C225&ssl=1 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/04/Lexaria-Corp-boost-1.jpg?w=480&ssl=1 480w" sizes="(max-width: 300px) 100vw, 300px" />
Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the “Company” or “Lexaria”) announces it has received US$91,443.50 from the exercise of warrants and options previously granted. The stock warrants were exercised at the price of US$0.14 and the stock options were exercised at US$0.2273 for a total of 636,025 common shares being issued. All warrants and options are being exercised by third parties who are neither officers nor directors of the Company.
No commissions or placement fees have been paid related to the funds received from these warrant and option exercises. Proceeds will be used for general corporate purposes.
Lexaria Bioscience Corp
Separately the Company has entered a consulting agreement with a third party that has resulted in the issuance of 500,000 warrants, each warrant good to buy one share at the price of US$0.44 and valid for exercise for one year.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.